Shining a light on brain aging: could NIR boost memory?
NCT ID NCT03551392
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This pilot study tests whether shining near infrared (NIR) light on the head and through the nose can improve memory, thinking, and mood in older adults without dementia. Participants will receive either real or sham NIR sessions over 12 weeks. The goal is to see if this gentle light therapy might support brain health as we age.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Near infrared (NIR) light delivered via the Medx Console System
- What this could lead to
- If effective, this could point toward a non-invasive way to support brain health and slow age-related cognitive decline.
- What could go wrong
- This is a small pilot study, so results may not apply broadly. The treatment is experimental, and its benefits are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
Jun 2019
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 to 89 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * No evidence of dementia or Mild Cognitive Impairment based on cognitive screening (i.e., Montreal Cognitive Assessment (MoCA) scores within normal limits for age , education, and sex using the NACC Uniform Data Set (UDS) norms or Dementia Rating Scale (DRS-2) scores \<5thile), and age-appropriate delayed Story recall (i.e., WMS-III Logical Memory) and confrontation naming (Boston Naming Test) * Able to provide informed consent and perform cognitive and mood measures on a computer * At least 8th grade education and/or ability to read at 8th grade level * Willingness to be randomized to Sham or Real intervention * Can devote 12 weeks to the intervention, and additional time for pre and post testing * On stable doses of major medications; Since some older adults with subjective memory complaints may be prescribed acetylcholinererase inhibitors or related medications by their primary care physicians (i.e., donepezil, rivastigmine, galantaominhe, memantime, or other potential memory-enhancing agent(s), we will not exclude them as long as they have been on stable medications for at least two months and plan to continue this medication during study participation. * Normal functional behavior in terms of daily activities Exclusion Criteria: * Previous major strokes or other known significant brain abnormalities or diseases affecting cognition (i.e., multiple sclerosis, seizure disorder, brain surgery, moderate TBI, etc.). No history of brain surgery. Exceptions are a diagnosis of Parkinson's disease for the PD subgroup. * Unstable and uncontrolled medical conditions (metabolic encephalopathy, HIV, moderate to severe kidney or liver disease) * Current or past history of major psychiatric disturbance including schizophrenia, or active psychosis, bipolar disorder, current major depressive episode, current alcohol or substance abuse or history thereof within the past six months. The study team is not excluding individuals who are taking antidepressants or anti-anxiety medications, however, use of antidepressants and anxiolytics will be recorded and data will be analyzed in post-hoc analyses * Use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory) * Use of photo-sensitive medications such as steroids or retin-A within 15 days of the study intervention * Diagnosis of active cancer * Significant motor or visual disturbance that would prevent one from using a computer or detecting colors * Previous participation in a cognitive training study within the last 3 months or current involvement in another study involving cognitive training or intervention at the time of participation * Inability to undergo brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, non-removable body jewelry, or shrapnel containing ferromagnetic metal
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aging are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Arizona
Tucson, Arizona, 85721, United States
-
University of Florida
Gainesville, Florida, 32611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sharing old memories boost mental Well-Being in old age?
- Can a Hands-On reflex therapy steady an older Person's stance?
- Scientists ask: when does a balance test score really improve?
- Gut check: can poop pills from young donors turn back the biological clock?
- Your smartwatch could soon warn you before you crash
- Can a tablet game rewire an aging brain to ignore distractions?